Loading
Gastric Cancer Management and Outcomes · Journal article
Journal of Gastrointestinal Cancer · September 11, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 121 patients with advanced gastric cancer shows that time-dependent mGPS 2 status during first-line chemotherapy ± nivolumab is associated with shorter overall survival (HR 2.17, 95% CI 1.15–4.10, P = 0.017) but not progression-free survival. The association does not differ significantly by nivolumab use. mGPS 2 status is a prognostic marker in this setting but does not appear to be a predictive marker of treatment benefit.
Retrospective cohort study. Patients with HER2-negative unresectable advanced or recurrent gastric cancer receiving first-line oxaliplatin- plus fluoropyrimidine-based chemotherapy. Median age 71 years; 63% male; 31% with baseline mGPS 2.. Intervention: First-line nivolumab-containing chemotherapy (oxaliplatin plus fluoropyrimidine plus nivolumab). Compared with: First-line chemotherapy without nivolumab (oxaliplatin plus fluoropyrimidine alone). n = 121.
Time-dependent mGPS 2 status associated with shorter OS: HR 2.17 (95% CI 1.15–4.10, P = 0.017) Time-dependent mGPS 2 status not associated with PFS: HR 1.49 (95% CI 0.69–3.20, P = 0.30) Cumulative proportion meeting mGPS 2 criterion by 6 months: 55% non-nivolumab group, 57% nivolumab-containing group
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize mGPS 2 status as an independent prognostic marker for overall survival in advanced gastric cancer during first-line chemotherapy. However, the association is not modified by nivolumab use, and the study does not establish mGPS 2 as a treatment-selection tool. Results are preliminary and require prospective validation before clinical implementation.
Retrospective cohort study identifying mGPS 2 as a time-dependent predictor of overall survival in advanced gastric cancer, but with modest sample size, observational design, and no practice-changing effect size or mechanistic clarity.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize mGPS 2 status as an independent prognostic marker for overall survival in advanced gastric cancer during first-line chemotherapy. However, the association is not modified by nivolumab use, and the study does not establish mGPS 2 as a treatment-selection tool. Results are preliminary and require prospective validation before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
PURPOSE: The clinical significance of longitudinal cachexia-related status during first-line therapy for advanced gastric cancer remains unclear in the era of nivolumab-containing chemotherapy. We evaluated its association with outcomes according to nivolumab use. METHODS: We retrospectively analyzed 121 patients with HER2-negative unresectable advanced or recurrent gastric cancer who received first-line oxaliplatin- plus fluoropyrimidine-based chemotherapy between 2017 and 2024. Modified Glasgow Prognostic Score (mGPS) 2 status and modified European Palliative Care Research Collaborative (EPCRC)-defined cachexia status were assessed as time-dependent covariates. Progression-free survival (PFS) and overall survival (OS) were analyzed using time-dependent Cox proportional hazards models. RESULTS: The cohort included 69 patients in the non-nivolumab group and 52 in the nivolumab-containing group. Median age was 71 years, 76 patients (63%) were male, and baseline mGPS 2 was present in 37 patients (31%). The cumulative proportion of patients who met the mGPS 2 criterion by 6 months was 55% in the non-nivolumab group and 57% in the nivolumab-containing group. Time-dependent mGPS 2 status was not significantly associated with PFS (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.69-3.20; P = 0.30), but was associated with shorter OS (HR, 2.17; 95% CI, 1.15-4.10; P = 0.017). No statistically significant interaction between time-dependent mGPS 2 status and nivolumab use was observed for PFS or OS. Time-dependent modified EPCRC-defined cachexia status was not significantly associated with PFS or OS. CONCLUSIONS: Time-dependent mGPS 2 status during first-line therapy was associated with shorter OS, but not PFS.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.